Most patients with AML and ALL have a high level of BCAA transporters (BCAT1), while serum BCAA levels are reduced, suggesting active absorption of BCAA (Kikushige et al., 2023) and the formation of secondary metabolites (dipeptides). Here, BCAT1 is linked to acute lymphoblastic leukemia.